Downregulation of FoxM1 sensitizes nasopharyngeal carcinoma cells to cisplatin via inhibition of MRN-ATM-mediated DNA repair |
Li, Dandan
(Department of Otolaryngology, The First Affiliated Hospital of Chongqing Medical University)
Ye, Lin (Department of cardiothoracic surgery, The First Affiliated Hospital of Chongqing Medical University) Lei, Yue (Laboratory Research Center, The First Affiliated Hospital of Chongqing Medical University) Wan, Jie (Department of Otolaryngology, The First Affiliated Hospital of Chongqing Medical University) Chen, Hongyan (Department of Otolaryngology, The First Affiliated Hospital of Chongqing Medical University) |
1 | Tauchi H, Kobayashi J, Morishima K et al (2002) Nbs1 is essential for DNA repair by homologous recombination in higher vertebrate cells. Nature 420, 93-98 DOI |
2 | Nestal de Moraes G, Bella L, Zona S, Burton MJ and Lam EW (2016) Insights into a critical role of the FOXO3a-FOXM1 axis in DNA damage response and genotoxic drug resistance. Curr Drug Targets 17, 164-177 DOI |
3 | Rocha CRR, Silva MM, Quinet A, Cabral-Neto JB and Menck CFM (2018) DNA repair pathways and cisplatin resistance: an intimate relationship. Clinics (Sao Paulo) 73, e478s DOI |
4 | Salehan MR and Morse HR (2013) DNA damage repair and tolerance: a role in chemotherapeutic drug resistance. Br J Biomed Sci 70, 31-40 DOI |
5 | Jiang L, Wang P, Chen L and Chen H (2014) Down-regulation of FoxM1 by thiostrepton or small interfering RNA inhibits proliferation, transformation ability and angiogenesis, and induces apoptosis of nasopharyngeal carcinoma cells. Int J Clin Exp Pathol 7, 5450-5460 |
6 | Zheng J, Zhang C, Jiang L et al (2011) Functional NBS1 polymorphism is associated with occurrence and advanced disease status of nasopharyngeal carcinoma. Mol Carcinog 50, 689-696 DOI |
7 | Jiang L, Wu X, Wang P et al (2015) Targeting FoxM1 by thiostrepton inhibits growth and induces apoptosis of laryngeal squamous cell carcinoma. J Cancer Res Clin Oncol 141, 971-981 DOI |
8 | Al-Sarraf M, LeBlanc M, Giri PG et al (1998) Chemoradiotherapy versus radiotherapy in patients with advanced nasopharyngeal cancer: phase III randomized Intergroup study 0099. J Clin Oncol 16, 1310-1317 DOI |
9 | Ziebarth AJ, Nowsheen S, Steg AD et al (2013) Endoglin (CD105) contributes to platinum resistance and is a target for tumor-specific therapy in epithelial ovarian cancer. Clin Cancer Res 19, 170-182 DOI |
10 | Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J and Jemal A (2015) Global cancer statistics, 2012. CA Cancer J Clin 65, 87-108 DOI |
11 | Yoshizaki T, Kondo S, Murono S et al (2015) Progress and controversy for the role of chemotherapy in nasopharyngeal carcinoma. Jpn J Clin Oncol 45, 244-247 DOI |
12 | Goldstein M and Kastan MB (2015) The DNA damage response: implications for tumor responses to radiation and chemotherapy. Annu Rev Med 66, 129-143 DOI |
13 | Lee AW, Sze WM, Au JS et al (2005) Treatment results for nasopharyngeal carcinoma in the modern era: the Hong Kong experience. Int J Radiat Oncol Biol Phys 61, 1107-1116 DOI |
14 | Lee AW, Poon YF, Foo W et al (1992) Retrospective analysis of 5037 patients with nasopharyngeal carcinoma treated during 1976-1985: overall survival and patterns of failure. Int J Radiat Oncol Biol Phys 23, 261-270 DOI |
15 | Galluzzi L, Senovilla L, Vitale I et al (2012) Molecular mechanisms of cisplatin resistance. Oncogene 31, 1869-1883 DOI |
16 | Paull TT and Lee JH (2005) The Mre11/Rad50/Nbs1 complex and its role as a DNA double-strand break sensor for ATM. Cell Cycle 4, 737-740 DOI |
17 | Frappart PO, Tong WM, Demuth I et al (2005) An essential function for NBS1 in the prevention of ataxia and cerebellar defects. Nat Med 11, 538-544 DOI |
18 | So S, Davis AJ and Chen DJ (2009) Autophosphorylation at serine 1981 stabilizes ATM at DNA damage sites. J Cell Biol 187, 977-990 DOI |
19 | Lamarche BJ, Orazio NI and Weitzman MD (2010) The MRN complex in double-strand break repair and telomere maintenance. FEBS Lett 584, 3682-3695 DOI |
20 | Laoukili J, Stahl M and Medema RH (2007) FoxM1: at the crossroads of ageing and cancer. Biochim Biophys Acta 1775, 92-102 |
21 | Koo CY, Muir KW and Lam EW (2012) FOXM1: From cancer initiation to progression and treatment. Biochim Biophys Acta 1819, 28-37 DOI |
22 | Bensouda Y, Kaikani W, Ahbeddou N et al (2011) Treatment for metastatic nasopharyngeal carcinoma. Eur Ann Otorhinolaryngol Head Neck Dis 128, 79-85 DOI |
23 | Zhou J, Wang Y, Wang Y et al (2014) FOXM1 modulates cisplatin sensitivity by regulating EXO1 in ovarian cancer. PLoS One 9, e96989 DOI |
24 | Park YY, Jung SY, Jennings NB et al (2012) FOXM1 mediates Dox resistance in breast cancer by enhancing DNA repair. Carcinogenesis 33, 1843-1853 DOI |
25 | Chua MLK, Wee JTS, Hui EP and Chan ATC (2016) Nasopharyngeal carcinoma. Lancet 387, 1012-1024 DOI |
26 | Kuo LJ and Yang LX (2008) Gamma-H2AX - a novel biomarker for DNA double-strand breaks. In Vivo 22, 305-309 |
27 | Wang KMsd, Chen ZMsd, Long LMsd et al (2018) iTRAQ-based quantitative proteomic analysis of differentially expressed proteins in chemoresistant nasopharyngeal carcinoma. Cancer Biol Ther 19, 1-16 DOI |
28 | Yu C, Chen L, Yie L et al (2015) Targeting FoxM1 inhibits proliferation, invasion and migration of nasopharyngeal carcinoma through the epithelialto-mesenchymal transition pathway. Oncol Rep 33, 2402-2410 DOI |
29 | Jiang L, Wang P and Chen H (2014) Overexpression of FOXM1 is associated with metastases of nasopharyngeal carcinoma. Ups J Med Sci 119, 324-332 DOI |
30 | San Filippo J, Sung P and Klein H (2008) Mechanism of eukaryotic homologous recombination. Annu Rev Biochem 77, 229-257 DOI |
![]() |